Junshi Biosciences Reports Final Phase 3 NEOTORCH Study Analysis
Junshi Biosciences announced final analysis results from its Phase 3 NEOTORCH study at ESMO Congress 2026.
Story updates
03:49:35 AM UTC
SquawkNews
Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in eve